121 related articles for article (PubMed ID: 17695408)
21. [Desmoid tumor of the chest wall infiltrating into the brachial plexus: report of a resected case].
Sakamoto K; Okita M; Takeuchi K; Nishida S; Mikami Y; Hayashi Y
Kyobu Geka; 2001 Feb; 54(2):160-3. PubMed ID: 11211773
[TBL] [Abstract][Full Text] [Related]
22. Function-sparing surgery for desmoid tumors and other low-grade fibrosarcomas involving the brachial plexus.
Maniker AH
Neurosurgery; 1998 Nov; 43(5):1260-1. PubMed ID: 9802876
[No Abstract] [Full Text] [Related]
23. Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial.
Chugh R; Wathen JK; Patel SR; Maki RG; Meyers PA; Schuetze SM; Priebat DA; Thomas DG; Jacobson JA; Samuels BL; Benjamin RS; Baker LH;
Clin Cancer Res; 2010 Oct; 16(19):4884-91. PubMed ID: 20724445
[TBL] [Abstract][Full Text] [Related]
24. Prediction of desmoid tumor progression using miRNA expression profiling.
Dufresne A; Paturel M; Alberti L; Philippon H; Duc A; Decouvelaere AV; Cassier P; Blay JY
Cancer Sci; 2015 May; 106(5):650-5. PubMed ID: 25707497
[TBL] [Abstract][Full Text] [Related]
25. Clinical, histopathologic, molecular and therapeutic findings in a large kindred with gastrointestinal stromal tumor.
Kleinbaum EP; Lazar AJ; Tamborini E; Mcauliffe JC; Sylvestre PB; Sunnenberg TD; Strong L; Chen LL; Choi H; Benjamin RS; Zhang W; Trent JC
Int J Cancer; 2008 Feb; 122(3):711-8. PubMed ID: 17943734
[TBL] [Abstract][Full Text] [Related]
26. Not all c-kit mutations can be corrected by imatinib.
Lasota J
Lab Invest; 2007 Apr; 87(4):317. PubMed ID: 17486696
[No Abstract] [Full Text] [Related]
27. Imatinib mesylate for melanoma: will a new target be revealed?
Grossman D
J Invest Dermatol; 2004 Dec; 123(6):xi-xiii. PubMed ID: 15610499
[No Abstract] [Full Text] [Related]
28. Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus.
Huh WK; Sill MW; Darcy KM; Elias KM; Hoffman JS; Boggess JF; Alvarez RD; Long HJ; O'Malley DM; Birrer MJ
Gynecol Oncol; 2010 May; 117(2):248-54. PubMed ID: 20189232
[TBL] [Abstract][Full Text] [Related]
29. Complete response after treatment with imatinib in pretreated disseminated testicular seminoma with overexpression of c-KIT.
Pedersini R; Vattemi E; Mazzoleni G; Graiff C
Lancet Oncol; 2007 Nov; 8(11):1039-40. PubMed ID: 17976614
[No Abstract] [Full Text] [Related]
30. C-kit as a target in the treatment of acute myelogenous leukemia.
Advani AS
Curr Hematol Rep; 2005 Jan; 4(1):51-8. PubMed ID: 15610660
[TBL] [Abstract][Full Text] [Related]
31. Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report.
Rapisuwon S; Parks K; Al-Refaie W; Atkins MB
Melanoma Res; 2014 Oct; 24(5):509-11. PubMed ID: 25003536
[TBL] [Abstract][Full Text] [Related]
32. OncoloGIST, BioloGIST, RadioloGIST: the big impact on the field of oncology of a molecularly-targeted therapy designed to treat a rare disease.
Demetri GD
Eur J Cancer; 2003 Sep; 39(14):1976-7. PubMed ID: 12957451
[No Abstract] [Full Text] [Related]
33. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a Phase II clinical trial.
Altundag O; Altundag K; Boruban C; Silay YS; Turen S
Cancer; 2005 Nov; 104(9):2033-4; author reply 2034. PubMed ID: 16161057
[No Abstract] [Full Text] [Related]
34. Good clinical response to imatinib mesylate in atypical thymic carcinoid With KIT overexpression.
Hamada S; Masago K; Mio T; Hirota S; Mishima M
J Clin Oncol; 2011 Jan; 29(1):e9-10. PubMed ID: 20876428
[No Abstract] [Full Text] [Related]
35. CD117 (c-kit) expression on CD34+ cells participates in the cytogenetic response to imatinib in patients with chronic myeloid leukemia in the first chronic phase.
Dybko J; Haus O; Jazwiec B; Urbaniak J; Wozniak M; Kaczmar-Dybko A; Urbaniak-Kujda D; Kapelko-Slowik K; Kuliczkowski K
Acta Haematol; 2014; 132(2):166-71. PubMed ID: 24577437
[TBL] [Abstract][Full Text] [Related]
36. [Imatinib].
Urabe A
Gan To Kagaku Ryoho; 2003 Aug; 30(8):1191-6. PubMed ID: 12938280
[TBL] [Abstract][Full Text] [Related]
37. c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571.
Vitali R; Cesi V; Nicotra MR; McDowell HP; Donfrancesco A; Mannarino O; Natali PG; Raschellà G; Dominici C
Int J Cancer; 2003 Aug; 106(2):147-52. PubMed ID: 12800187
[TBL] [Abstract][Full Text] [Related]
38. STI-stop transplanting immediately?
Klingemann HG
J Hematother Stem Cell Res; 2002 Apr; 11(2):165-7. PubMed ID: 11983089
[No Abstract] [Full Text] [Related]
39. Positron emission tomography as a surrogate marker for evaluation of treatment response in patients with desmoid tumors under therapy with imatinib.
Kasper B; Dimitrakopoulou-Strauss A; Pilz LR; Strauss LG; Sachpekidis C; Hohenberger P
Biomed Res Int; 2013; 2013():389672. PubMed ID: 23762842
[TBL] [Abstract][Full Text] [Related]
40. Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands.
Faivre S; Raymond E; Casiraghi O; Temam S; Berthaud P
J Clin Oncol; 2005 Sep; 23(25):6271-3; author reply 6273-4. PubMed ID: 16135502
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
